Clearpoint Neuro, Inc. (CLPT)
NASDAQ:CLPT
Top Page
ClearPoint Neuro
(NASDAQ:CLPT)
Select Model
Select Model
Rating:47Neutral
Price Target:
$9.00
▼(-67.06% Downside)
Action:ReiteratedDate:03/17/26
The score is held down primarily by weak financial quality (large losses, heavier leverage, and increased cash burn) and bearish technical trend signals. Partially offsetting these are a more positive earnings-call setup with strong 2026 revenue guidance and sustained ~61% gross margins, while valuation remains challenged due to negative earnings and no dividend support.
Positive Factors
Consistent Revenue Growth
Multi-year, double-digit top-line growth demonstrates persistent market adoption of ClearPoint’s platform and consumables. A growing installed base and rising procedure volume support recurring disposable pull-through, making revenue expansion a durable driver of future scale and margin leverage.
Negative Factors
Heavy Cash Burn
Significant negative operating and free cash flow implies ongoing external funding need, which can dilute shareholders or raise financing costs. Persistent cash burn constrains the company’s ability to self-fund R&D, commercialization, and acquisitions over the coming 2–6 months without new capital.
Read all positive and negative factors
Positive Factors
Negative Factors
Consistent Revenue Growth
Multi-year, double-digit top-line growth demonstrates persistent market adoption of ClearPoint’s platform and consumables. A growing installed base and rising procedure volume support recurring disposable pull-through, making revenue expansion a durable driver of future scale and margin leverage.
Read all positive factors
ClearPoint Neuro (CLPT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$257.48M
Dividend YieldN/A
Average Volume (3M)950.71K
Price to Earnings (P/E)―
Beta (1Y)1.65
Revenue Growth12.83%
EPS Growth-19.53%
CountryUS
Employees115
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.26
Shares Outstanding29,663,876
10 Day Avg. Volume498,024
30 Day Avg. Volume950,706
Financial Highlights & Ratios
PEG Ratio-0.53
Price to Book (P/B)13.82
Price to Sales (P/S)10.48
P/FCF Ratio-15.84
Enterprise Value/Market Cap1.05
Enterprise Value/Revenue7.32
Enterprise Value/Gross Profit11.92
Enterprise Value/Ebitda-12.08
Forecast
1Y Price Target
$25.00Price Target Upside-8.49% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.8
Revenue Forecast (FY)$55.50M
ClearPoint Neuro Business Overview & Revenue Model
Company Description
ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. The company develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under direct, and intra-procedural mag...
How the Company Makes Money
ClearPoint Neuro primarily generates revenue by selling and supporting its neurosurgical navigation platform and the consumables used with it. Key revenue streams typically include: (1) capital equipment sales (and/or placements) of the ClearPoint...
ClearPoint Neuro Earnings Call Summary
Earnings Call Date:Mar 17, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 12, 2026
Earnings Call Sentiment Neutral
The call conveyed strong commercial and clinical momentum — year-over-year revenue growth, a significantly larger cash balance from recent financing, important regulatory clearances (PRISM 1.5T, CE for 3.X), an expanding partner and clinical footprint (>60 partners, 25+ trials), and an operational roadmap (CAL facility, robotics). At the same time, the business is managing notable near-term headwinds from increased operating expenses (notably G&A +38%), elevated cash burn from operations ($23.9M), higher interest expense following financing, acquisition-related one-time costs and assumed liabilities, and some removed upside due to stricter FDA positioning on rare-disease approval pathways. Management provided a constructive 2026 revenue guide ($52M–$56M) but acknowledged regulatory and integration risks that could affect timing of upside.Positive Updates
Full-Year and Q4 Revenue Growth
Total revenue for FY2025 was $37.0M, up from $31.4M in 2024 (+17.8%). Fourth quarter revenue was $10.4M versus $7.8M a year earlier (+33.3%), representing the strongest financial quarter of 2025.
Negative Updates
Rising Operating Expenses
Operating expenses increased materially in 2025: R&D up to $13.9M (+12% YoY), sales & marketing $16.5M (+14% YoY) and general & administrative $16.5M (+38% YoY). G&A growth was driven by severance, professional services and higher personnel costs.
Read all updates
Q4-2025 Updates
Positive
Negative
Full-Year and Q4 Revenue Growth
Total revenue for FY2025 was $37.0M, up from $31.4M in 2024 (+17.8%). Fourth quarter revenue was $10.4M versus $7.8M a year earlier (+33.3%), representing the strongest financial quarter of 2025.
Read all positive updates
Company Guidance
On the call management set 2026 revenue guidance at $52.0–$56.0 million — a range tightened to reflect recent FDA communications around rare-disease approvals and integration priorities from the November 20, 2025 Eris acquisition (Eris contributed $1.2M of 2025 revenue and historically ran roughly $8–9M a year) — while noting FY2025 revenue was $37.0M (up from $31.4M in 2024) and Q4/2025 revenue was $10.4M (vs. $7.8M a year earlier). They reiterated expectations that all four core product segments (pre‑commercial biologics & drug delivery, neurosurgery navigation & robotics, laser therapy & access, and neurocritical management/EarFlo) will each grow in the double digits in 2026, highlighted a FY2025 gross margin of ~61% (Q4 62%), and summarized FY2025 expenses of R&D $13.9M, sales & marketing $16.5M, and G&A $16.5M. Key operational metrics supporting the outlook include cash & equivalents of $45.9M at 12/31/2025, net cash used in operations of $23.9M in 2025, an installed base of >150 global centers, >60 active biopharma partners, >25 active clinical trials across >15 indications, and >10 partner programs in some form of FDA expedited review; management said the guidance excludes meaningful commercial drug‑delivery revenue (so regulatory upside would be incremental) and reiterated a longer‑term aim to capture ~20% of a combined $1.0B market (~$200M revenue) on the path toward a potential $500M business, with sustainable organic growth expectations in the mid‑teens to ~20% range.ClearPoint Neuro Financial Statement Overview
Summary
Income Statement
32
Negative
Balance Sheet
28
Negative
Cash Flow
25
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 36.97M | 31.39M | 23.95M | 20.55M | 16.30M |
| Gross Profit | 22.69M | 19.12M | 13.61M | 13.53M | 11.12M |
| EBITDA | -21.93M | -17.84M | -20.99M | -15.58M | -12.74M |
| Net Income | -25.54M | -18.91M | -22.09M | -16.43M | -14.41M |
Balance Sheet | |||||
| Total Assets | 97.75M | 39.19M | 42.66M | 55.49M | 65.58M |
| Cash, Cash Equivalents and Short-Term Investments | 45.92M | 20.10M | 23.14M | 37.49M | 54.11M |
| Total Debt | 58.23M | 3.57M | 13.94M | 11.99M | 12.28M |
| Total Liabilities | 69.73M | 13.80M | 21.49M | 18.60M | 16.79M |
| Stockholders Equity | 28.02M | 25.39M | 21.17M | 36.89M | 48.79M |
Cash Flow | |||||
| Free Cash Flow | -24.45M | -9.22M | -14.44M | -16.42M | -12.87M |
| Operating Cash Flow | -23.93M | -8.95M | -13.72M | -16.17M | -12.70M |
| Investing Cash Flow | 615.00K | -275.00K | 8.95M | -10.74M | -168.00K |
| Financing Cash Flow | 50.18M | 6.19M | 296.00K | 409.00K | 46.88M |
ClearPoint Neuro Technical Analysis
Negative
27.32
Price Trends
11.41
Negative
12.78
Negative
14.11
Negative
Market Momentum
-0.70
Negative
35.99
Neutral
36.74
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CLPT, the sentiment is Negative. The current price of 27.32 is above the 20-day moving average (MA) of 9.46, above the 50-day MA of 11.41, and above the 200-day MA of 14.11, indicating a bearish trend. The MACD of -0.70 indicates Negative momentum. The RSI at 35.99 is Neutral, neither overbought nor oversold. The STOCH value of 36.74 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CLPT.
ClearPoint Neuro Risk Analysis
ClearPoint Neuro disclosed 56 risk factors in its most recent earnings report. ClearPoint Neuro reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
ClearPoint Neuro Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | $753.38M | 21.81 | 4.97% | ― | 1.58% | ― | |
56 Neutral | $567.08M | -45.38 | -12.91% | ― | 23.27% | 43.90% | |
54 Neutral | $659.48M | 35.21 | -8.56% | ― | 2.70% | -3090.51% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $496.99M | -6.56 | -20.38% | ― | 4.31% | 3.26% | |
47 Neutral | $257.48M | -15.17 | -122.17% | ― | 12.83% | -19.53% |
* Healthcare Sector Average
CLPT
ClearPoint Neuro
8.68
-2.79
-24.32%
OFIX
Orthofix Medical
12.38
-1.29
-9.44%
AVNS
Avanos Medical
14.18
1.71
13.71%
SIBN
SI-Bone
12.84
-0.53
-3.96%
BVS
Bioventus
9.06
1.58
21.12%
ClearPoint Neuro Corporate Events
Business Operations and StrategyFinancial DisclosuresM&A TransactionsPrivate Placements and Financing
ClearPoint Neuro Reports Record 2025 Results, Expands Growth Outlook
Positive
Mar 17, 2026
ClearPoint Neuro, Inc., based in Solana Beach, Calif., is a global medical device and therapy-enabling company focused on precise navigation for the brain and spine. Its portfolio spans biologics and drug delivery tools, neurosurgery navigation an...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.